How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
65
CRVS Quote, Financials, Valuation and Earnings
Last price:
$20.67
Seasonality move
:
-15.85%
Day range:
$20.20 - $21.71
52-week range:
$2.54 - $26.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
21.79x
Volume:
2.3M
Avg. volume:
5.7M
1-year change:
291.3%
Market cap:
$1.6B
Revenue:
--
EPS (TTM):
-$0.53
Analysts' Opinion
-
Consensus RatingCorvus Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.33, Corvus Pharmaceuticals, Inc. has an estimated upside of 59.19% from its current price of $20.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 4.49% downside risk from its current price of $20.70.
Fair Value
-
According to the consensus of 6 analysts, Corvus Pharmaceuticals, Inc. has 59.19% upside to fair value with a price target of $33.33 per share.
CRVS vs. S&P 500
-
Over the past 5 trading days, Corvus Pharmaceuticals, Inc. has underperformed the S&P 500 by -18.58% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Corvus Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Corvus Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Corvus Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Corvus Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Corvus Pharmaceuticals, Inc. reported earnings per share of -$0.12.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
-46.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$99K
Return On Assets:
-21.11%
Net Income Margin (TTM):
--
Return On Equity:
-30.6%
Return On Invested Capital:
-30.03%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$217K | -$92K | -$99K | -$20K | -$28K | |
| Operating Income | -$23.4M | -$25.1M | -$38.9M | -$7.3M | -$10.6M | |
| EBITDA | -$23.2M | -$25M | -$38.8M | -$7.2M | -$10.5M | |
| Diluted EPS | -$0.64 | -$0.93 | -$0.53 | -$0.60 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $78.8M | $51.3M | $33.1M | $42.9M | $66.9M | |
| Total Assets | $119.3M | $80.3M | $51.9M | $58.8M | $80.5M | |
| Current Liabilities | $11.3M | $14M | $7.3M | $46.4M | $8.1M | |
| Total Liabilities | $14.2M | $15.7M | $7.7M | $46.4M | $8.7M | |
| Total Equity | $105.1M | $64.7M | $44.3M | $12.4M | $71.8M | |
| Total Debt | $3.9M | $1.7M | $354K | -- | $632K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.3M | -$22.1M | -$32.1M | -$6.3M | -$9.6M | |
| Cash From Investing | $14M | -$23.7M | -$24.8M | -$3.9M | -$2.6M | |
| Cash From Financing | $7.9M | $30.4M | $55M | $50K | $360K | |
| Free Cash Flow | -$26.3M | -$22.1M | -$32.2M | -$6.3M | -$9.6M | |
CRVS
Sector
Market Cap
$1.6B
$24.3M
Price % of 52-Week High
77.7%
49.95%
Dividend Yield
0%
0%
Shareholder Yield
-10.01%
-1.67%
1-Year Price Total Return
312.21%
-21.37%
Beta (5-Year)
0.703
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$22.51
200-day SMA
Buy
Level
$6.47
Bollinger Bands (100)
Buy
Level
4.4 - 13.18
Chaikin Money Flow
Sell
Level
-1.6M
20-day SMA
Buy
Level
$13.93
Relative Strength Index (RSI14)
Buy
Level
69.76
ADX Line
Sell
Level
7.14
Williams %R
Neutral
Level
-29.2315
50-day SMA
Buy
Level
$10.59
MACD (12, 26)
Buy
Level
2.94
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-161.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.0566)
Sell
CA Score
(Annual)
Level (-2.0734)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (6.9887)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, CRVS has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRVS average analyst price target in the past 3 months is $33.33.
-
Where Will Corvus Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Corvus Pharmaceuticals, Inc. share price will rise to $33.33 per share over the next 12 months.
-
What Do Analysts Say About Corvus Pharmaceuticals, Inc.?
Analysts are divided on their view about Corvus Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corvus Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Corvus Pharmaceuticals, Inc.'s Price Target?
The price target for Corvus Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $33.33 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Corvus Pharmaceuticals, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRVS?
You can purchase shares of Corvus Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corvus Pharmaceuticals, Inc. shares.
-
What Is The Corvus Pharmaceuticals, Inc. Share Price Today?
Corvus Pharmaceuticals, Inc. was last trading at $20.67 per share. This represents the most recent stock quote for Corvus Pharmaceuticals, Inc.. Yesterday, Corvus Pharmaceuticals, Inc. closed at $20.70 per share.
-
How To Buy Corvus Pharmaceuticals, Inc. Stock Online?
In order to purchase Corvus Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CRVS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CRVS
Sector
P/E ratio
--
23.45x
PEG ratio
-0.06x
-0.01x
P/B ratio
21.79x
1.80x
Price / LTM sales
--
1.53x
Growth Metrics
CRVS
Sector
Revenue growth
--
4.08%
Earnings growth
79.67%
9.94%
Revenue (5-year growth)
--
6.27%
Earnings forecast
-$0.13
-$0.19
Profitability
CRVS
Sector
Profitability FY 2024
-$85K
$3M
Return on invested capital
-30.03%
-33.25%
Return on assets
-21.11%
-29.67%
Return on equity
-30.6%
-38.71%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
4
Estimated Next Earnings Date
Feb
3
Balance Sheet
CRVS
Sector
Total cash
$65.7M
$25M
Short term investments
$43.2M
$25M
Total assets
$68.9M
$72.5M
Long term debt
$632K
$2.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
78
GDXU alert for Jan 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
88
JNUG alert for Jan 30
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
